Cargando…

Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment

BACKGROUND: Pharmacogenetic testing holds major promise in allowing physicians to tailor therapy to patients based on genotype. However, there is little data on the impact of pharmacogenetic test results on patient and clinician choice of therapy. CYP2D6 testing among tamoxifen users offers a potent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorizio, Wendy, Rugo, Hope, Beattie, Mary S, Tchu, Simone, Melese, Teri, Melisko, Michelle, Wu, Alan HB, Lawrence, H Jeffrey, Nikoloff, Michele, Ziv, Elad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239226/ https://www.ncbi.nlm.nih.gov/pubmed/21970596 http://dx.doi.org/10.1186/gm280

Ejemplares similares

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

Amelioration of sexual adverse effects in the early breast cancer patient
por: Melisko, Michelle E., et al.
Publicado: (2010)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos
por: Rangel-Méndez, Jorge-Aarón, et al.
Publicado: (2019)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Tamoxifen--the treatment of choice. Why look for alternatives?
por: Baum, M.
Publicado: (1998)

Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions
por: Jeiziner, Chiara, et al.
Publicado: (2021)

Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
por: Vidula, Neelima, et al.
Publicado: (2021)

The ethics of CYP2D6 testing for patients considering tamoxifen
por: Hartman, Anne-Renee, et al.
Publicado: (2007)

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
por: Caudle, Kelly E., et al.
Publicado: (2017)

The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge
por: Hernandez-Boussard, Tina, et al.
Publicado: (2008)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Development of a high-throughput differential mobility separation–tandem mass spectrometry (DMS-MS/MS) method for clinical urine drug testing
por: Hooshfar, Shirin, et al.
Publicado: (2022)

The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)‐Endoxifen in Breast Cancer
por: Nardin, Jeanine Marie, et al.
Publicado: (2019)

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
por: Caudle, Kelly E., et al.
Publicado: (2019)

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population
por: Verma, Shefali S., et al.
Publicado: (2022)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Pharmacogenetics Informed Decision Making in Adolescent Psychiatric Treatment: A Clinical Case Report
por: Smith, Teri, et al.
Publicado: (2015)

Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship–Associated Distress: Survey Study
por: Umashankar, Saumya, et al.
Publicado: (2022)

Relevance of G-quadruplex structures to pharmacogenetics
por: Cree, Simone L., et al.
Publicado: (2014)

Considering Genomic Scans for Selection as Coalescent Model Choice
por: Harris, Rebecca B, et al.
Publicado: (2020)

COVID-19 vaccine decisions: considering the choices and opportunities
por: Hotez, Peter J., et al.
Publicado: (2021)

Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Cancer pharmacogenetics
por: Marsh, S, et al.
Publicado: (2004)

Experimental Pharmacogenetics
por: Lubs, Herbert A.
Publicado: (1964)

Pharmacogenetics of Anticoagulants
por: Rane, Anders, et al.
Publicado: (2010)

Pharmacogenetics of osteoporosis
por: Marini, Francesca, et al.
Publicado: (2010)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

Pharmacogenetics in the clinic
por: Guchelaar, H.-J.
Publicado: (2013)

Pharmacogenetics of Cannabinoids
por: Hryhorowicz, Szymon, et al.
Publicado: (2017)

Pharmacogenetics of thiopurines
por: Franca, Raffaella, et al.
Publicado: (2019)

Should bioprostheses be considered the valve of choice for dialysis-dependent patients?
por: Zhibing, Qiu, et al.
Publicado: (2013)

An experimental investigation into whether choice architecture interventions are considered ethical
por: Turetski, Daniella, et al.
Publicado: (2023)

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2020)

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
por: Wigle, Theodore J., et al.
Publicado: (2017)

Comparison of probabilistic choice models in humans
por: Takahashi, Taiki, et al.
Publicado: (2007)

Providing choice of feedback affects perceived choice but does not affect performance
por: Ziv, Gal, et al.
Publicado: (2022)

Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dth7iq3l5t1t1pec7ervv4okhn